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ABSTRACT 
Plasma peptides are widely used in clinical diagnosis and therapy monitoring. Our aim was an efficient 
system development for the enrichment of small, low abundant peptides from plasma by robotized 
sample preparation. The automation of SPE yields additional time saving and improves system 
robustness and repeatability. Automation is based on combining a Waters SPE kit with Oasis HLB sorbent 
and a multichannel liquid handling workstation with cheap commercially available electronic devices 
such as a programmable logic controller (PLC) and an AVR controller. Reversed phase nano liquid 
chromatography coupled with a sensitive quadrupole time of flight mass spectrometer (QTOF MS) and it 
was used for the quantitative determination of somatostatin (SST). We quantified SST from mouse 
plasma, where lower limit of detection (LLOD) and lower limit of quantification (LLOQ) were 2.5 and 8.3 
fmol/ml, respectively. We investigated linearity of response, accuracy, precision, recovery, reproducibility 
and stability of SST during both short-term sample processing and long-term storage. This method allows 
reliable quantification of plasma peptides. The developed automated sample preparation solid phase 
extraction method can be easily and conveniently adopted for different volumes and amounts of sample 
in routine analysis using controlled vacuum. The highest advantage is enhanced reproducibility, which 
makes it suitable for the investigations of large sample cohorts in clinical studies.   
GRAPHICAL ABSTRACT 
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Introduction 
The neuropeptide somatostatin (SST) is a cyclic tetradecapep-
tide, which was first isolated from sheep hypothalamic cells. 
SST exists in two main forms: quantitatively predominant, 
but less bioactive SST-14 (consisting of 14 amino acids) and 
more bioactive SST-28 (NH2-terminally extended 28 amino 
acid form).[1] SST is found in a wide range of tissues including 
the central nervous system and peripheral tissues.[4] SST is 
known to play an important role in the hypothalamic 
regulation of growth hormone secretion and inhibits 
the release of thyrotropin releasing hormone, dopamine and 
norepinephrine. It is a potential mediator of antidepressant 
effects.[25] In the peripheral nervous system SST has inhibitory 
effects on nociception and inflammatory processes.[27] SST 
exerts a number of effects on neuroendocrine, cognitive 
behavioral, autonomic and visceral functions.[8] Disorders in 
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SST metabolism have been proposed to contribute to various 
psychiatric and neurological disorders SST concentrations in 
general are correlated with neurological and psychiatric 
disease states. Levels of SST are consistently decreased in the 
cerebrospinal fluid of patients with Alzheimer’s disease and 
frontotemporal dementia. Reductions have also been reported 
in patients with multiple sclerosis or depression.[2,5,11,19,20] 
Somatostatin-14 has a very short serum and plasma half-life 
(2–3 min) and due to this the therapeutic use of it is limited, but 
analogues of the hormone are used for certain diseases. During 
laboratory procedures this time can be prolonged using inhibitors 
and keeping samples at cold temperature. That decreases the 
susceptibility of this compound to endogenous proteases.[21] 
Mass spectrometry (MS) has become an important tool in the 
study of neuropeptides through the method’s ability to directly 
detect ions at a given mass-to-charge (m/z) ratio, even in complex 
biological mixtures (for example plasma, urine, cerebrospinal 
fluid, saliva etc.). The fastest way to determine the identity of 
peptide fragments produced by neuropeptide-processing, 
-converting, or inactivating of enzymes is to use matrix-assisted 
laser desorption ionization (MALDI) MS. SST-14 due to its high 
concentration in the tissue can be measured from brain 
sections directly with MALDI–time-of-flight (TOF) MS.[28] 
Quantification of peptides in general can be achieved by several 
techniques. Liquid chromatographic separation followed predo-
minantly by electrospray ionization MS represents a sensitive 
and robust technique, but radioimmunoassay (RIA)[21,26] and 
chromatography with UV detection are also in use. Identification 
of SSTs has already been published with LC–MS from 
hypothalamic samples, where the authors used in situ hybridiza-
tion to follow changes in the gene expression.[25] 
Solid phase extraction (SPE) is a valuable and widely used 
technique for the purification and selective extraction of 
complex biological samples (plasma, urine etc.). The use of a 
96-well SPE block can save time and is cost-effective. The 
automation of SPE yields additional time saving and improves 
system robustness and repeatability. Generally, automated SPE 
systems are applied in investigations of small molecules, in 
pharmacokinetics screening studies for example VLA-4 
antagonists,[29] doramectin[14] and neurotransmitters from 
blood,[17] toxicology monitoring for example tetrahydrocanna-
binol and metabolites from urine.[16] Automated peptide and 
protein analysis requires more complicated methods.[3,6,17] 
Our primary aim was the quantitative determination of the 
neuropeptide from blood samples. Blood samples contain 
significantly lower concentration of SST-14 than hypothalamic 
samples therefore we used reversed phase nano liquid 
chromatography coupled with a sensitive quadrupole TOF 
MS. We aimed to develop a method ideal for clinical 
laboratories. Therefore, we automated the complete sample 
pretreatment to make it quick, precise, highly repeatable and 
fit for the analysis of large number of samples. 
Materials and methods 
Chemicals and reagents 
The SST-14 standard and trifluoro-acetic acid were purchased 
from Fluka Chemie AG (Buchs, Switzerland). Solvents, 
ultrapure water, methanol and acetonitrile (Hipersolv, 
Chromanorm LC–MS grade) were purchased from VWR 
(Radnor, PA, USA). LC–MS grade CHROMASOLV formic 
acid, acetic acid, ammonium-hydroxide were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Amicon Ultra 10 
MWCO centrifugal filter devices (CFD) were from 
Merck-Millipore (Darmstadt, Germany). The SPE kit with 
Oasis HLB 96 well plates was obtained from Waters (Milford, 
MA, United States). 
Animals and sample pretreatment 
Bagg Albino (20–25 g) mouse strain (BALB/c) were obtained 
from Charles River, Hungary and bred in the Animal Centre 
of the University of Pécs under standard pathogen-free 
conditions. 
Animals were fed and watered ad libitum under light/dark 
cycles of 12/12 hr. All procedures were performed in 
accordance with the ethical guidelines and under approved 
protocols (ethical permission number: University of Pecs 
BA02/2000-15024/2011). 
Blood samples were collected by cardiac puncture under 
ketamine (100 mg/kg i.p., Richter, Hungary) and xylazine 
(5 mg/kg i.p., Lavet, Hungary) anesthesia. The animals were 
fasted overnight before sampling to avoid gastrointestinal 
SST-14 release. The cooled Protein Lobind tubes (Eppendorf, 
Wien, Austria) contained 40 µl protease inhibitor (EDTA) 
and 20 µl peptidase inhibitor cocktail (Sigma-Aldrich, 
Hungary) and aprotinin (Trasylol, Bayer, Germany). Blood 
samples were centrifuged at 1,000 rpm for 5 min and 
10,000 rpm for 10 min at 4°C to separate plasma. Plasma were 
stored at   20°C until further processing. During the total 
sample collection and preparation LoRetention tips 
(Eppendorf, Wien, Austria) were used to avoid protein lost. 
Six mice were used in the animal study. 
Instrumentation 
Extraction was achieved by an eight channel Hamilton 
Microlab Starlet liquid handling workstation (Hamilton Co., 
Bonaduz, GR, Switzerland). This robot was controlled by a 
PLC (Siemens S7 300) and an AVR controller (Amtel 
atmega8). We connected a membrane vacuum pump (GAS 
DOA 504) to the extraction system and an SMC vacuum 
controller valve (SMC ITV 009). 
Control of protein removal was performed with an Autoflex 
II TOF/TOF MALDI–MS instrument (Bruker, Bremen, 
Germany). 
For the Analysis of SST-14 we used an EASY II nanoLC— 
Maxis 4G UHR-QTOF MS (Bruker, Bremen, Germany) 
system. 
Automation 
The complete sample preparation has been automated. 1 ml 
water was used for washing, than the phase was activated with 
1 ml mixture of methanol/water (v/v, 1/1). 200 µl 0.1% TFA 
(in water) was added to 800 µl sample and it was loaded 
to the phase. 1 ml methanol/water/ammonium-hydroxide 
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(v/v/v, 5/93/2) and 1 ml methanol/water/acetic acid (v/v/v, 
5/93/2) solutions were used alternately to wash the plate twice, 
respectively. The extracted components were eluted from 
the phase with 500 µl of methanol/water/formic acid (v/v/v, 
65/33/2). 
The developed method and extraction was integrated to the 
automated system, which consisted of the liquid handling 
workstation and an external SPE system. To spare time and 
to enhance reproducibility we integrated the SPE kit—which 
was designed for manual use—into the liquid handling work-
station. The physical dimensions of the vacuum manifold of 
the Waters SPE-kit (175 mm � 125 mm) allowed us to fix it 
on the motherboard of the workstation. We connected the 
membrane vacuum pump and the PLC to control it. We 
designed and set up an AVR controller between the software 
of the workstation (Hamilton Venus two 4.3) and the PLC 
to ensure online communication. We applied impulse modu-
lated communication through a plugin type assembly program 
directly between the USB port of the computer and the digital 
input card of the PLC (Figure 1) as a trigger. We covered the 
unused parts of the Oasis 10 mg HLB 96-well plate cartridges 
with a polyethylene foil as we had to maintain the vacuum, 
while the full capacity of the well plate was not used. On 
SPE cartridges smooth flow parameters must continuously 
be ensured to get good reproducibility. Due to the differing 
number and the uneven viscosities of the samples vacuum 
fluctuations could occur. To compensate these we built in a 
feedback type vacuum control system. The vacuum measurer 
built in the manifold is directly connected to the PLC which 
uses a proportional-integral-derivative algorithm and a 
vacuum controller valve to compensate quickly and precisely 
the deviation from the value of reference signal. A flexible 
controller program was written for the robot which supports 
different numbers and types of samples without any change 
in the script. The program uses selection, sequence, iteration, 
local and global variable declaration supported by the 
Hamilton Venus two software and it was provided by a gra-
phic panel. That way we have a complete sample pretreatment 
system, which can easily be used by any operator including 
end users without programming experience. 
After SPE, sample eluates were loaded in CFD and 
centrifuged at 10,000 rpm for 30 min to remove proteins and 
particles. Filtrates were tested by MALDI TOF/TOF and if 
protein was found the filtration had been repeated. The 
protein free filtrates were loaded into autosampler vials and 
nanoLC–MS was carried out (Figure 2). 
MALDI-TOF control of effectiveness of protein 
excluding 
Despite of the cautious pretreatment protein residues cannot 
always removed perfectly. We applied quick MALDI–TOF 
measurements to test our samples of any possible remaining 
proteins (Figure 2),[22] which could later be precipitated 
and cause column blockage. To carry out these controlling 
experiments an Autoflex II MALDI–TOF/TOF MS (Bruker 
Daltonics, Bremen, Germany) was used. The system was 
controlled by Flexcontrol 3.4. Data was evaluated using 
Flexanalysis 3.4. The centrifuged samples were enriched on a 
Protein Anchor chip target plate (MTPAnchorChip™384 T F, 
Bruker Daltonics, Bremen, Germany) by using 1 µl of sample 
solution. After that 1 µl freshly prepared diluted (0.7 mg/ml) 
α -cyano-4-hydroxycinnamic acid in acetonitrile/0.1% TFA 
(1/2, v/v) solution was spotted onto the samples. The mass 
spectrometer was equipped with a 1 kHz Smart beam II 
solid-state Nd:YAG UV laser (Lasertechnik Berlin GmbH, 
Berlin, Germany). The instrument was operated in linear 
mode. The accelerating voltage was set to 20.00 kV. External 
calibration was performed using Bruker Protein II Calibration 
Standard (#207234, Bruker Daltonics). Protein masses were 
acquired in the mass range of 5–80 kDa. 
NanoLC–MS 
Separation was performed by Bruker Easy nanoLC II (Bruker 
Daltonics, Bremen, Germany) using a 100 mm � 75 µm 
Figure 1. Scheme illustration of automated SPE sample preparation system.    
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(3 µm) C18 Thermo Easy-Column (Unicam Kft, Budapest, 
Hungary) and a 20 mm � 100 µm (5 µm) C18 pre-column at 
23°C. The injected volume was 1 µl for each analysis. The 
autosampler was set to 4°C. A binary gradient consisting 
of mobile phases A and B (A: water-0.1% formic acid, B: 
acetonitrile-0.1% formic acid,) was applied. The gradient 
profile was 10–30% B in 2 min, than 30–80% in 28 min. The 
column was washed with 90% B for 6.5 min and equilibrated 
to the initial conditions with a 1 min linear gradient and an 
isocratic period of 6.5 min. 
The mass analyzer was a Bruker Maxis 4G UHR-QTOF MS 
instrument (Bruker Daltonics, Bremen, Germany) coupled 
with a nano-ESI source. The instrument was controlled by 
the software Compass 1.3 (Bruker Daltonics, Bremen, 
Germany). The mass spectrometer was operated in positive 
mode. The scanning mass-to-charge range was m/z 
100–3,000 at 1 Hz acquisition rate. Nitrogen was used as 
nebulizer gas pressure was set to 0.6 bar, drying gas flow was 
7 l/hr at 180°C and the capillary voltage was set to 3.8 kV. 
The quantification and data evaluation were performed by 
the Data Analysis v.3.4 software (Bruker Daltonics, Bremen, 
Germany), peak picking was achieved by applying Apex 
algorithm on extracted ion chromatograms (EIC). 
Results and discussion 
SST-14 determination by nanoLC–MS 
Earlier, we used a specific sensitive RIA method for the 
measurement of SST-like immunoreactivity in human plasma 
and other biological samples.[24] This analytical technique 
requires minimum 3 ml plasma. Since only 1 ml blood can 
be obtained from a mouse, this method was not optimal in 
the present animal experiment. The adoption of MS-based 
methodologies for peptide analysis has been relatively slow. 
This is in part due to the difficulty of achieving the same level 
of sensitivity of immunological methods.[18] The main cause 
of low sensitivity is that the peptide ion current is divided 
amongst the multiple charge states that are commonly 
observed in electrospray ionization.[18] Summation of different 
transitions can compensate to some extent the loss in signal 
intensity inherent to the appearance of multiple charge 
states.[10] The combination of an effective sample preparation 
method and the use of up-to-date instruments can enable 
peptides to be detected with sensitivities similar to 
immunological-based approaches.[18] 
Oasis HLB extraction products, which was used to SPE, 
contain a resin made from a co-polymer of divinybenzene 
and vinyl pyrrolidinone. The pyrrolidinone functionality acts 
as an imbedded hydrophilic group thereby provides wetting 
properties. The pyrrolidinone functionality also provides 
enhanced retention for some polar analytes. The diviny-
benzene, as liphophilic monomer provides reversed-phase 
property for analyte retention. It was used to peptide desalting 
and separation but the number of shared peptides only 45% 
were same compared to reversed-phase C18. That can be 
explained with the completely different chemistry of the 
stationary phases.[12] 
Reversed-phase LC is an important tool for peptide separ-
ation. In contrast to the well-understood chromatographic 
behavior of small molecules, the behaviour of peptides under 
different chromatographic conditions are more complicate.[30] 
For example, as expected, mobile phase related factors had 
a significant influence on the retention for most peptides as 
well as on MS sensitivity. TFA as ion-pairing reagent in the 
mobile phase was clearly very detrimental to peak area com-
pared to formic acid. TFA is a strong and rather hydrophobic 
acid that forms stable ion-pairs with positively charged amino 
acid residues, enhancing peptide retention on the column. On 
the other hand, formic acid is a weaker acid that forms more 
labile ion-pairs, which is beneficial to analyte ionization in the 
MS source, but is less favourable to peptide retention on the 
stationary phase.[15] Furthermore, the retention behaviour of 
the peptides with different charge are variable and the relative 
peak areas are affected by ionization efficiency of peptides 
in different TFA conditions.[13] Thus, TFA, as ion-pairing 
reagent was not use for the analytical separation, only in the 
automated SPE processes. 
Two SST-14 ions were observed by nanoLC–MS, doubly 
charged (819.8 m/z) and triply charged (546.9 m/z). The triply 
charged ion was more intense and the ratio of the two SST-14 
ions was constant (3.62 � 0.02). The peptide sequence was 
confirmed by MSMS. Similarly to Dillen,[9] the acceptable 
fragmentation was only observed for the triply charged ion. 
The doubly charged peptide breaks only down to fragments 
at high collision energy and the obtained fragment ions have 
lower intensity compared to fragment ions obtained from 
the triply charged peptide.[9] Therefore, quantification was 
based on the cumulative peak areas of the triply charged 
(546.9 � 0.05 m/z) and doubly charged ion (819.8 � 0.05 m/z). 
NanoLC–MS method validation 
Our sensitive nanoLC–MS method enabled us the determi-
nation of SST-14 from mouse plasma containing protease 
and peptidase inhibitors. Validation was also performed in 
plasma. We investigated linearity of response, accuracy, pre-
cision, recovery, reproducibility and stability of SST-14 during 
Figure 2. Schematic experimental workflow.  
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both short-term sample processing and long-term storage. The 
linearity of the method was determined by a weighted least 
square regression analysis of standard plot associated with a 
five-point standard curve. Analytical curve was found to 
be linear in the range of 0.16–900 fmol/ml. Correlation 
coefficients (R2) were consistently greater than 0.995 during 
the course of validation. The LLOD (3S/N) and the LLOQ 
(10S/N) were 2.5 and 8.3 fmol/ml; they were calculated from 
EICs of 10 fmol/ml standard solution. These detection limits 
are similar to earlier described,[9] where 3 pmol/ml (5 ng/ml) 
SST was determined by high-resolution TOF MS and 
600 fmol/ml (1 ng/ml) by triple quadrupole MS as LLOQ. 
Reproducibility was summarized in Table 1. The deviation 
of intra- and inter-day precisions were �9.7%, whereas intra- 
and inter-day accuracies were in the range of 92.3–108.9%. 
These results indicate that the method’s precision and 
accuracy were adequate for the level of analyte concentration 
in the samples. The applied nanoLC runtime was relatively 
long (44 min), however, using a column selector and an extra 
pump the runtime could be decreased. 
Automated assay validation 
With the PLC instrument we were able to interconnect the 
liquid handling workstation; the SPE kits and the external 
vacuum pump online (Figure 1). The developed PLC method 
contained 384 commands. Our online system is flexible; we 
can easily adjust it to different volumes (100–1,500 µl) and 
different number of samples (1–96). Online sample prep-
aration had to be interrupted only for protein removal, which 
was achieved on CFDs (Figure 2). Processing of a full loaded 
plate (96 samples) required less than half an hour. With this 
automated SPE system using proper solid phase and eluting 
program different components of plasma (proteins, peptides, 
lipids, metabolites etc.) can be extracted. 
During method development we investigated reproduci-
bility, recovery and various stability indicators of the Waters 
stationary phase by nanoLC–MS. For that purpose, plasma 
samples were used, which were stored at room temperature 
for 24 hr without inhibitors (protease inhibitor EDTA, 
peptidase inhibitor cocktail, aprotinin). This storage resulted 
in SST-14-free (<LLOD, data not found) plasma samples 
due to degradation. They were spiked with fresh SST-14 
standards to the final concentration of 1, 10, 100 fmol/ml 
and they were added the inhibitor cocktail. SST-14 could be 
identified with nanoLC–MS using automated SPE system 
(Figure 3). Spiked plasma samples were used for recovery 
experiments. Recoveries (�SD) were found at the three 
different concentration levels (1, 10, and 100 fmol/mL), and 
found to be 73.8% (�9.9), 88.28% (�4.5), and 79.8% (�6.0), 
respectively. These results indicate that the automatic SPE 
efficiency for SST was satisfactory, and consistent in the 
examined concentration range. 
Samples were at room temperature only during preparation 
and SPE; they were kept at 4°C in the autosampler of the 
nanoLC otherwise at   80°C. The stability of the SST-14 spiked 
samples were investigated at two concentration levels (10 
and 100 fmol/ml) to cover expected conditions during 
analysis, storage, and sample processing, which include the 
stability data from various stability exercises like bench-top, 
freeze/thaw, processed sample, and long-term stability tests 
Table 1. Intra-day and inter-day precision and accuracy for the analysis of 
SST-14 in standard solution (calculated from data from six separate runs), n ¼ 6. 
Nominal  
concentration  
(fmol/ml) 
Measured  
concentration  
(fmol/ml � SD) 
Precision  
(CV, %) 
Accuracy  
(recovery, 
%)  
Intra-day variation 
1  0.96 � 0.08  8.3  96.1 
10  10.89 � 0.92  8.5  108.9 
100  97.52 � 3.52  3.6  97.5 
Inter-day variation 
1  0.92 � 0.07  7.6  92.3 
10  10.55 � 1.02  9.7  105.5 
100  99.06 � 4.56  4.6  99.1    
Figure 3. Analysis of the mouse sample by SPE-nanoLC–MS system. Panel a: EIC 
of triply charged somatostatin (m/z 546.9), b: mass spectrum of the peak at 
10.3 min, m/z 819.8 is the doubly charged somatostatin, m/z 546.9 is triply charged 
somatostatin. The calculated SST-14 concentration was 24.9 fmol/ml.  
Table 2. Precision and accuracy for the analysis of SST-14 in spiked plasma 
(calculated from data from six separate sample) were measured at three different 
stability conditions, n ¼ 6. 
Nominal  
concentration  
(fmol/ml) 
Measured  
concentration  
(fmol/ml) 
Precision  
(CV, %) 
Accuracy  
(recovery, 
%)  
Bench top stability 
10  9.01 � 0.99  11.0  90.1 
100  93.62 � 5.70  6.0  93.6 
Processed sample 
10  9.34 � 0.87  9.3  93.4 
100  95.93 � 5.65  5.9  95.9 
Freeze-thaw 
10  8.87 � 0.95  10.7  88.7 
100  91.06 � 4.94  5.4  91.1    
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(Table 2). The stability results indicate that SST-14 spiked 
mouse plasma samples were stable for at least 6.0 hr at room 
temperature, for at least 48 hr in final extract at 15°C 
when stored in the autosampler and during three 
freeze-thaw cycles when stored at around   80°C and thawed 
to room temperature. 
Animal study 
To prove biological applicability we analyzed six mouse 
plasma samples, which showed little differences in the 
concentration of SST-14. The average concentration was 
24.1 � 2.21 fmol/ml (Table 3). This value is approximately 
the half of the concentration found in previous study.[7] The 
reason of finding lower concentration of SST-14 compared 
to literature data probably comes from cross reactivity of 
radio-immunoassay technics, which causes an increase in the 
signal.[23] 
Conclusions 
A reliable, selective and specific analytical method for the 
determination of SST-14 in plasma samples has been 
developed and validated. Samples were prepared by 
automatic SPE, separated on a C18 column and quantified 
by nanoLC–MS. This method exhibited adequate sensitivity, 
acceptable precision and excellent stability for the quantifi-
cation of SST-14 in mouse plasma containing protease and 
peptidase inhibitors. 
Automation in general can increase the sample throughput 
and also increases repeatability, stability, precision, and accu-
racy. The added values of our system are the integration of 
the SPE into the liquid handling robot and the use of controlled 
vacuum. Controlled vacuum plays a very important role in the 
reproducibility of SPE. In future, the method could be applied 
in vivo and clinical tests with large sample cohorts. 
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